Apolipoprotein News and Research

RSS

Early life experiences influence risk of cognitive impairment in later life

Early life experiences, such as childhood socioeconomic status and literacy, may have greater influence on the risk of cognitive impairment late in life than such demographic characteristics as race and ethnicity, a large study by researchers with the UC Davis Alzheimer's Disease Center and the University of Victoria, Canada, has found.

26 Jul 2014

Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step closer to the goal of developing the world's first T-cell peptide-based vaccine for heart disease - the number one killer in the nation.

17 Jul 2014

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.

15 Jul 2014

Eye exam for beta-amyloid correlates with levels in brain, detects people with Alzheimer's

A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer's disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer's, in the brain, according to the results of four research trials reported today at the Alzheimer's Association International Conference- 2014 (AAIC- 2014) in Copenhagen.

14 Jul 2014

Study explores prevalence of chronic brain damage in retired NFL players

A study published online today in Sports Health: A Multidisciplinary Approach provides a different take on previous information regarding the prevalence of chronic brain damage in retired NFL players.

26 Jun 2014

Study: Apolipoprotein E mimetic peptide protects against diffuse brain injury

Because the majority of patients with diffuse brain injury are not suitable candidates for surgery, neuroprotective agents are of great importance.

28 May 2014

People with longevity gene have improved brain skills

Scientists showed that people who have a variant of a longevity gene, called KLOTHO, have improved brain skills such as thinking, learning and memory regardless of their age, sex, or whether they have a genetic risk factor for Alzheimer's disease.

12 May 2014

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.

9 May 2014

Studies demonstrate new approaches to treating and preventing Parkinson's disease

A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease.

29 Apr 2014

Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease

A study of older adults at increased risk for Alzheimer's disease shows that moderate physical activity may protect brain health and stave off shrinkage of the hippocampus- the brain region responsible for memory and spatial orientation that is attacked first in Alzheimer's disease.

25 Apr 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

A fast, non-invasive method to genotype late-onset Alzheimer's disease

The apolipoprotein E gene ε4 allele is considered a negative factor for neural regeneration in late-onset Alzheimer's disease cases.

27 Mar 2014

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).

19 Mar 2014

Healthy dietary choices in midlife may prevent dementia in later years

Healthy dietary choices in midlife may prevent dementia in later years, according a doctoral thesis published at the University of Eastern Finland. The results showed that those who ate the healthiest diet at the average age of 50 had an almost 90 per cent lower risk of dementia in a 14-year follow-up study than those whose diet was the least healthy.

10 Mar 2014

Study investigates associations between self-rated physical fitness and dementia risk

How would you rate your own physical fitness? Is it good, satisfactory or maybe even poor? Surprisingly, your answer may reveal your future risk of getting dementia.

26 Feb 2014

Cleveland Clinic: Process that turns HDL cholesterol bad discovered

Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) - the so-called "good cholesterol" - becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries.

26 Jan 2014

Presence of gene variant in people with MCI associated with accelerated rates of brain atrophy

The presence of a gene variant in people with mild cognitive impairment is associated with accelerated rates of brain atrophy, according to a new study published online in the journal Radiology.

15 Jan 2014

African Americans have double the risk of end-stage renal disease compared to white Americans

In the United States, African Americans have approximately twice the risk of end-stage renal disease compared to white Americans, despite a similar prevalence in earlier stages of chronic kidney disease. A large study co-authored by George Washington University researcher Dominic Raj, M.D., identifies factors that mediate differences in the progression of chronic kidney disease between black patients and white patients, as well as among black patients, in order to reduce the excess burden of end-stage renal disease and its complications in black patients.

27 Nov 2013

Sinai Hospital reports results from Phase 2a trial of apo A-I infusion therapy CSL112

Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.

22 Nov 2013

Genetic variations in African Americans with kidney disease contribute to rapid decline in kidney function

New research provides direct evidence that genetic variations in some African Americans with chronic kidney disease contribute to a more rapid decline in kidney function compared with white Americans.

10 Nov 2013